I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the Homepage after clicking on No.

Respiratory Hub

In 2022, Zentiva partnered with COVIS to expand our respiratory portfolio. We are excited to relaunch these products into the respiratory market space.

Please browse through the following educational materials to see how our products can help your patients.

Alvesco® 80 and 160 Inhaler (ciclesonide)

Alvesco® is indicated in treatment to control persistent asthma in adults and adolescents (12 years and older)1.

Alvesco® allows you to treat inflammation effectively, with a low potential for adverse events, even at high doses, due to its:

  • High total lung deposition2
  • Low throat deposition3
  • High systemic clearance1,4

Alvesco® Mode of Action Videos

Lung Deposition

Throat Deposition

Side Effects


Duaklir® Genuair®▼340 micrograms /12 micrograms, inhalation powder (aclidinium/formoterol fumarate dihydrate)

Duaklir® Genuair® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)5.

Duaklir® Genuair® offers:

  • improved symptom control during night and day, compared to placebo and monotherapies6
  • no dose adjustment required in patients with renal- or hepatic impairment or in elderly patients5
  • the benefit of the Genuair® inhaler with high acceptability and confidence for patients as result of easy use and the feedback system7,8

The GOLD 2024 guidelines recommend LAMA/LABA's such as Duaklir® Genuair® as the initial treatment for most COPD patients.

The Genuair® Device

The Genuair® inhaler is a multidose, breath-actuated DPI, with an integral visible and audible dose indicator7.

  • The inhaler has been designed to provide visual and audible feedback to ensure that medication is taken properly7.
  • Additionally, a dose indicator and a lock-out mechanism prevent the use of an empty inhaler7.
  • Effective dispersion of the inhalation powder is possible due to an optimised mechanism: the cyclone dispersion system7.
  • The inhaler is delivered ready to use and does not require powder reservoir insertion or refilling7.

Want to hear more about these products?

We draw your attention to the fact that this form should not be used to report a medical problem. In this case seek the advice of your doctor. If you have any questions about any of our products or if you wish to report an adverse event whether or not mentioned in the package leaflet, or the Legal Notice, contact us.

Complete this form to order your training devices:
Name
Place of Work
Units
Confirm you are not sending a spam
Marketing Consent

We thank you for your interest in our products. We will do what is necessary to respond to your request as soon as possible.
By submitting the form I declare that I accept the Legal Notice & Privacy Notice and have read and understood the Privacy Notice.

Adverse events on Alvesco and Duaklir should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Covis via email to medinfoEMEA@covispharma.com
or via phone on 08004334029.

References:

1Alvesco® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/13890/smpc#gref
2Leach C et al, J Allergyu Clin immunol 2009; 129: 88-93
3Newman S et al, Respir Med 2006; 100: 375-383
4Derendorf H et al, Eur Respir J 2006; 28: 1042-1050
5Duaklir® Genuair® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/14789/smpc#gref [last accessed January 2024].
6Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16(1):92.
7Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012 Mar;66(3):309-17. doi: 10.1111/j.1742-1241.2011.02832.x. PMID: 22340451.
8Magnussen H, Fyrnys B, Greguletz R. Genuair®/Pressair® Inhaler in COPD: The Patient Perspective. COPD. 2019 Apr;16(2):196-205. doi: 10.1080/15412555.2019.1630807.
Epub 2019 Jul 2. PMID: 31264482.

Alvesco® is a registered trademark of Covis Pharma GmbH. Duaklir® is a registered trademark of Almirall S.A. Genuair® is a registered trademark of the AstraZeneca group of companies.

Date of preparation: January 2024 | Ref: 000571436